Sie sind hier: Startseite Reseachers Oliver Schilling

Oliver Schilling

Schilling, Oliver
Prof. Dr. rer. nat,
Institute of Surgical Pathology, Faculty of Medicine, University of Freiburg
Breisacher Str. 115A, D-79106, Freiburg
oliver.schilling[a]mol-med.uni-freiburg.de
 
Current position
Heisenberg Professor (W3) of Translational Proteomics, Institute of Surgical Pathology

 

 

 

Research topic in GRK 2606: Exopeptidases in cell communication

University training and degree(s)
1994 − 2000   Studies in Biology in Münster, Germany, and Tours, France (Diplom-Biologe)
 
Advanced academic qualifications
2014                  Habilitation (Venia Legendi) in Molecular Medicine, University of Freiburg
2000 − 2004      PhD, European Molecular Biology Laboratory and University of Münster
 
Postgraduate professional career
since 2018      Heisenberg Professor (W3) of Translational Proteomics,
                           Institute of Surgical Pathology, Freiburg, Germany
2008  – 2018   Independent research group leader, Institute for Molecular Medicine and Cell
                           Research, University of Freiburg, Germany
2005 − 2008    Postdoctoral fellow in the group of Prof. Christopher M. Overall, University of British Columbia,
                           Vancouver, Canada
2004                Postdoctoral fellow, European Molecular Biology Laboratory
 
Other
2017                  Heisenberg programme of the DFG
2015                  Offer for Professorship  “Protein Chemistry” VetMed Uni Vienna, Austria, (declined)
2012 – 2017      Starting Grant of the European Research Council (awarded in 2011)
since 2011         Member, Centre for Biological Signalling Studies BIOSS,
since 2011         Principal Investigator, Spemann, Graduate School of Biology and Medicine
2009 – 2014      Emmy-Noether funding of the DFG
 
10 Important Publications
  1. Oria, V.O., Lopatta, P., Schmitz, T., Preca, B.T., Nyström, A., Conrad, C., Bartsch, J.W., Kulemann, B., Hoeppner, J., Maurer, J., Bronsert, P., Schilling, O. (2019). ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Mol. Oncol. 13, 456-479
  2. Zhang, H.E., Hamson, E.J., Koczorowska, M.M., Tholen, S., Chowdhury, S., Bailey, C.G., Lay, A.J., Twigg, S.M., Lee, Q., Roediger, B., Biniossek, M.L., O'Rourke, M.B., McCaughan, G.W., Keane, F.M., Schilling, O., Gorrell, M.D. (2019). Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics. Mol. Cell. Proteomics 18, 65-85
  3. Oria, V.O., Bronsert, P., Thomsen, A.R., Föll, M.C., Zamboglou, C., Hannibal, L., Behringer, S., Biniossek, M.L., Schreiber, C., Grosu, A.L., Bolm, L., Rades, D., Keck, T., Werner, M., Wellner, U.F., Schilling, O. (2018). Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. Transl. Oncol. 11, 1307-1322.
  4. Chen, C.Y., Melo, E., Jakob, P., Friedlein, A., Elsässer, B., Goettig, P., Kueppers, V., Delobel, F., Stucki, C., Dunkley, T., Fauser, S., Schilling, O.*, Iacone, R. (2018). N-Terminomics identifies HtrA1 cleavage of thrombospondin-1 with generation of a proangiogenic fragment in the polarized retinal pigment epithelial cell model of age-related macular degeneration. Matrix Biol. 70, 84-101. *corresponding author
  5. Röst, H.L., Sachsenberg, T., Aiche, S., Bielow, C., Weisser, H., Aicheler, F., Andreotti, S., Ehrlich, H.C., Gutenbrunner, P., Kenar, E., Liang, X., Nahnsen, S., Nilse, L., Pfeuffer, J., Rosenberger, G., Rurik, M., Schmitt, U., Veit, J., Walzer, M., Wojnar, D., Wolski, W.E., Schilling, O., Choudhary, J.S., Malmström, L., Aebersold, R., Reinert, K., Kohlbacher, O. (2016). OpenMS: a flexible open-source software platform for mass spectrometry data analysis. Nat. Methods 13, 741-8.
  6. Biniossek, M.L., Niemer, M., Maksimchuk, K., Mayer, B., Fuchs, J., Huesgen, P.F., McCafferty, D.G., Turk, B., Fritz, G., Mayer, J., Haecker, G., Mach, L., Schilling, O. (2016). Identification of Protease Specificity by Combining Proteome-Derived Peptide Libraries and Quantitative Proteomics. Mol. Cell. Proteomics 15, 2515-24.
  7. Lai, Z.W., Weisser, J., Nilse L., Costa, F., Keller, E., Tholen, M., Kizhakkedathu, J.N., Biniossek, M, Bronsert, P., Schilling, O. (2016). Formalin-Fixed, Paraffin-Embedded Tissues as a Robust Source for the Profiling of Native and Protease-Generated Protein Amino Termini. Mol. Cell. Proteomics 15, 2203-13.
  8. Tholen, S., Wolf C., Mayer, B., Knopf, J.D., Löffek, S., Qian, Y., Kizhakkedathu, J.N., Biniossek, M.L., Franzke, C.W., Schilling, O. (2016). Skin Barrier Defects Caused by Keratinocyte-Specific Deletion of ADAM17 or EGFR Are Based on Highly Similar Proteome and Degradome Alterations. J. Proteome Res. 15, 1402-17.
  9. Koczorowska, M.M., Tholen, S., Bucher, F., Lutz, L., Kizhakkedathu, J.N., De Wever, O., Wellner, U.F., Biniossek, M.L., Stahl, A., Lassmann, S., Schilling, O. (2016). Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol. Oncol. 10, 40-58.
  10. Shahinian, H., Loessner, D., Biniossek, M.L., Kizhakkedathu, J.N., Clements, J.A., Magdolen, V., Schilling O. (2014). Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells. Mol. Oncol. 8, 68-82